TP53 and lung cancer: A previous melanoma study identified a negative association between TP53-associated aneuploidy and response to CTLA-4 inhibitors (42), while studies in non–small cell lung cancer and esophagogastric adenocarcinoma tissue have found TP53 and HR mutations predicted response to immune checkpoint blockade (43, 44).